Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions
Novartis

Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever Syndrome conditions.

Its label now includes Tumor Necrosis Factor-Receptor Associated Periodic Syndrome (TARPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF).

The decision was based on results from the phase III CLUSTER study, which showed rapid and sustained disease control in patients treated with the interleukin-1 beta inhibitor over the course of 16 weeks.

Paul Hudson, Novartis Pharmaceuticals' chief executive, said: “Gaining three FDA approvals of Ilaris is a momentous turning point for people who suffer with these severe, debilitating diseases.

“There is a significant unmet need in these conditions, particularly in children, and Novartis is proud to provide a new treatment option to those who so desperately need it.”

The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis (SJIA), the most aggressive form of juvenile arthritis.

The biologic was first approved in both the US and EU in 2009 for the treatment of rare genetic disorder Cryopyrin-Associated Periodic Syndromes (CAPS), which is believed to occur in around 2,500 people in Europe - though many are still thought to be undiagnosed.

Periodic Fever Syndromes cause disabling and recurrent fevers that are often accompanied by joint pain, muscle pain, skin rashes and swelling, with most patients presenting symptoms in early childhood. 

Article by
Rebecca Clifford

27th September 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics